<DOC>
	<DOCNO>NCT00638833</DOCNO>
	<brief_summary>To assess efficacy Memantine improve cognitive impairment patient Multiple Sclerosis ( MS )</brief_summary>
	<brief_title>Memantine Therapy Multiple Sclerosis</brief_title>
	<detailed_description>Memantine NMDA receptor antagonist improve cognitive behavioural deficit patient Alzheimer disease , vascular dementia mixed dementia . This study focus prove efficacy Memantine ameliorate one frequent symptom patient MS attention memory deficit . Memantine safe drug patient MS administer MS patient pendular nystagmus ( Starck et al J Neurol 1997 ) . The study power detect difference clinical question study 60 MS patient cognitive impairment ( n=60 ) ) crossover design . Indeed , plan use new powerful surrogate marker attention evoke potential develop center . Finally , evidence Memantine might improve MS outcome close Brain-Blood barrier ( best therapeutic target disease ) ( Paul et al J Pharmacol Exp Ther 2002 ) , exploratory study efficacy prevent new MRI lesion might also include design . Aims : To assess efficacy Memantine improve cognitive impairment patient Multiple Sclerosis ( MS ) Primary end-point : ass efficacy Memantine improve memory deficit MS patient use SRT scale Secondary end-points : 1 . To assess efficacy Memantine improve performance individual neuropsychological test attention ( PASAT3 , SDMT , Stroop ) , executive ( Raven , MATTIS ) memory ( 10/36 , SRT ) , neuropsychological global scale BRB-N Z ( Sepulcre et al , submit ) quality life ( SF36 ) , disability ( EDSS , MSFC , MSSS ) fatigue ( Krupp ) . 2. assess effect Memantine attention evoke potential ( EP ) 3. assess effect Memantine clinical course ( new relapse , relapse rate , patient free relapse ) , disability ( EDSS , MSFC , MSSS ) MRI parameter ( active lesion : new T2 lesion , change T2 lesion load , new gadolinium enhance lesion global regional atrophy ) response Memantine . MRI study optional . 4. identify predictor good bad response Memantine therapy use EP surrogate marker . Design : double blind , randomize crossover clinical trial Memantine compare placebo MS patient . Because Memantine hal-life 2 4 day period , end 6 month , patient stay 3 week without therapy ( placebo Memantine ) order washout Memantine therapeutic group</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Patients MS ( McDonald 2002 ) , sex , age 18 60 year old , MS subtypes ( RR , SP , PP , PR ) , stable . Patients severe cognitive impairment define perform 1.5 SD control group ( match age education ) 2 subtests base previous study ( Sepulcre 2006 ) : Psychiatric disease ( Cummings ) depression ( Hamilton &gt; 8 ) , drug alcohol abuse , benzodiazepine therapy medical disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>